News

Evrysdi Approved in Brazil for SMA, But No Indications Specified

Evrysdi (risdiplam) has been approved for the treatment of spinal muscular atrophy (SMA) in Brazil by the country’s National Health Surveillance Agency, known as ANVISA. The Brazilian approval came within seven months of Roche’s original submission, with the country becoming the second to approve the medicine,…

PAN Foundation Offers Financial Help for SMA Treatment

People living with spinal muscular atrophy (SMA) who need financial help to pay for treatment may now apply for aid through a new patient assistance program offered by the PAN Foundation. The foundation’s new program will provide up to $6,500 annually to each eligible patient. The money…

Risdiplam, Oral SMA Treatment, Up for Approval in Japan

Chugai Pharmaceutical, part of the Roche Group, is asking that risdiplam be approved as a daily oral treatment for spinal muscular atrophy (SMA) patients in Japan. A new drug application seeking approval, submitted to that country’s Ministry of Health, Labour and Welfare (MHLW), may be given priority review…